Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
Website: interpace.com



Growth: Good revenue growth rate 33.3%, there is acceleration compared to average historical growth rates 4.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +15.9%. On average the margin is improving steadily. Gross margin is high, +61.1%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 25% of quarters (showing a gain of -$0.96 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 19.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 112.3% higher than minimum and 65.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 71.5% undervalued

Key Financials (Download financials)

Ticker: IDXG
Share price, USD:  (0.0%)1.19
year average price 0.9690  


year start price 0.8500 2025-01-12

min close price 0.5606 2025-01-13

max close price 1.5200 2025-12-09

current price 1.1900 2026-01-11
Common stocks: 4 229 940

Dividend Yield:  0.0%
FCF Yield LTM: 19.9%
EV / LTM EBITDA: 10.7x
EV / EBITDA annualized: 9.4x
EV / Sales: 1.7x
Margin (EBITDA LTM / Revenue): 15.9%
Fundamental value created in LTM:
Market Cap ($m): 5
Net Debt ($m): 70
EV (Enterprise Value): 75
Price to Book: -16.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-01-31globenewswire.com

Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

2025-01-09globenewswire.com

Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

2024-07-29globenewswire.com

Interpace Diagnostics® Announces Undefined Extension of Medicare Coverage for PancraGEN®, a Molecular Diagnostic Test That Assesses Cancer Risk of Pancreatic Cysts
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2024-04-01 2023-11-08 2023-08-09 2023-05-12 2023-03-27 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-01 17:01:09 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 9M 9M 12M 12M 10M 10M 9M 11M 10M 8M 8M
costOfRevenue 3M 4M 5M 5M 4M 4M 4M 4M 4M 3M 3M
grossProfit 5M 5M 8M 7M 6M 6M 5M 7M 6M 5M 5M
grossProfitRatio 0.621 0.571 0.61 0.617 0.591 0.594 0.524 0.62 0.608 0.601 0.578
researchAndDevelopmentExpenses 150 000 173 000 199 000 146 000 137 000 152 000 149 000 186 000 149 000 77 000 191 000
generalAndAdministrativeExpenses 2M 3M 3M 2M 2M 2M 2M 3M 2M 2M 3M
sellingAndMarketingExpenses 2M 3M 3M 3M 3M 3M 2M 3M 2M 2M 2M
sellingGeneralAndAdministrativeExpenses 4M 6M 5M 5M 5M 5M 5M 5M 5M 4M 5M
otherExpenses 0 0 0 71 000 -82 000 -259 000 0 -174 000 318 000 318 000 318 000
operatingExpenses 4M 6M 6M 5M 5M 5M 5M 6M 5M 5M 6M
costAndExpenses 8M 10M 10M 10M 9M 9M 9M 10M 9M 8M 9M
interestIncome 0 0 0 0 0 -775 000 256 000 259 000 0 -36 000 0
interestExpense 0 49 000 145 000 188 000 216 000 234 000 256 000 259 000 260 000 265 000 268 000
depreciationAndAmortization 111 000 199 000 85 000 188 000 160 000 43 812 240 000 358 000 375 000 -873 000 418 000
ebitda 1M -285 000 2M 2M 1M 1M 224 000 1M 1M -731 000 -362 000
ebitdaratio 0.127 -0.031 0.13 0.203 0.101 0.133 0.025 0.092 0.107 -0.088 -0.044
operatingIncome 1M -468 000 2M 2M 874 000 1M -16 000 832 000 675 000 142 000 -780 000
operatingIncomeRatio 0.131 -0.051 0.155 0.187 0.085 0.128 -0.002 0.075 0.069 0.017 -0.095
totalOtherIncomeExpensesNet -145 000 42 000 -539 000 -117 000 -298 000 -500 000 -508 000 -174 000 -241 000 -2M -485 000
incomeBeforeTax 1 000 000 -426 000 1M 2M 576 000 819 000 -524 000 399 000 434 000 -1M -1M
incomeBeforeTaxRatio 0.114 -0.046 0.111 0.178 0.056 0.08 -0.058 0.036 0.044 -0.168 -0.154
incomeTaxExpense 11 000 107 000 4000 4000 4000 6000 4000 4000 4000 5000 -11 000
netIncome 911 000 -640 000 1M 2M 468 000 890 000 -614 000 175 000 351 000 -1M -1M
netIncomeRatio 0.104 -0.069 0.104 0.171 0.046 0.087 -0.068 0.016 0.036 -0.169 -0.153
eps 0.23 -0.14 0.29 0.47 0.11 0.21 -0.14 0.04 0.08 -0.33 -0.3
epsdiluted 0.04 -0.14 0.29 0.47 0.11 0.2 -0.14 0.04 0.08 -0.33 -0.3
weightedAverageShsOut 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M
weightedAverageShsOutDil 28M 4M 4M 4M 4M 4M 4M 4M 4M 4M 4M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2024-04-26 2023-11-08 2023-08-09 2023-05-12 2023-03-27 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-26 16:39:36 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1M 502 000 2M 2M 3M 3M 5M 5M 6M 5M 6M
shortTermInvestments 0 0 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 1M 502 000 2M 2M 3M 3M 5M 5M 6M 5M 6M
netReceivables 6M 7M 7M 6M 5M 5M 5M 6M 5M 5M 5M
inventory 0 973 000 0 1M 1M 1M 1M 1M 1M 1M 1M
otherCurrentAssets 2M 798 000 2M 710 000 444 000 614 000 43 000 48 000 172 000 180 000 138 000
totalCurrentAssets 9M 10M 11M 10M 9M 10M 11M 13M 12M 12M 13M
propertyPlantEquipmentNet 3M 3M 3M 3M 3M 3M 3M 3M 3M 3M 1M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 27 000 226 000 544 000 861 000 1M
goodwillAndIntangibleAssets 0 0 0 0 0 0 27 000 226 000 544 000 861 000 1M
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 45 000 45 000 45 000 44 999 44 999 45 000 45 000 45 000 45 000 45 000 80 000
totalNonCurrentAssets 3M 3M 3M 3M 3M 3M 3M 3M 3M 4M 3M
otherAssets 0 0 0 1 1 0 0 0 0 0 0
totalAssets 12M 12M 14M 13M 12M 13M 14M 16M 16M 16M 15M
accountPayables 1M 1M 2M 2M 1M 2M 1M 2M 2M 1M 1M
shortTermDebt 0 2M 0 7M 8M 5M 414 000 2M 3M 3M 3M
taxPayables 0 223 000 259 000 308 000 276 000 261 000 238 000 222 000 279 000 262 000 85 000
deferredRevenue 0 0 0 308 000 276 000 261 000 10M 9M 0 0 0
otherCurrentLiabilities 5M 3M 17M 10M 9M 10M 858 000 858 000 10M 10M 10M
totalCurrentLiabilities 6M 7M 19M 19M 19M 17M 12M 14M 14M 14M 15M
longTermDebt 864 000 974 000 1M 1M 1M 4M 13M 13M 13M 13M 10M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 6M 5M 5M 5M 6M 6M 51M 52M 52M 52M 57M
totalNonCurrentLiabilities 6M 6M 6M 6M 8M 11M 65M 65M 65M 65M 62M
otherLiabilities 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 0 1M 1M 2M 1M 1M 2M 2M 2M 2M 852 000
totalLiabilities 12M 14M 25M 25M 27M 28M 77M 78M 78M 79M 77M
preferredStock 0 0 0 47M 47M 47M 47M 47M 47M 0 0
commonStock 407 000 407 000 406 000 406 000 406 000 405 000 405 000 405 000 405 000 405 000 404 000
retainedEarnings -233M -234M -244M -246M -248M -248M -249M -248M -249M -249M -247M
accumulatedOtherComprehensiveIncomeLoss 0 0 -47M -93M 0 -404 999 -47M -47M 0 0 0
othertotalStockholdersEquity 233M 233M 279M 372M 186M 187M 186M 186M 139M 186M 185M
totalStockholdersEquity -298 000 -1M -11M -12M -15M -15M -63M -62M -63M -63M -62M
totalEquity -298 000 -1M -11M -12M -15M -15M -63M -62M -63M -63M -62M
totalLiabilitiesAndStockholdersEquity 12M 12M 14M 13M 12M 13M 14M 16M 16M 16M 15M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 12M 12M 14M 13M 12M 13M 14M 16M 16M 16M 15M
totalInvestments 0 0 0 0 0 0 0 0 0 0 0
totalDebt 864 000 3M 1M 8M 11M 11M 14M 15M 16M 16M 13M
netDebt -559 000 3M -924 000 6M 8M 8M 9M 10M 10M 11M 7M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG IDXG
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-12 2025-08-07 2024-11-08 2024-08-08 2024-05-09 2024-04-01 2023-11-08 2023-08-09 2023-05-12 2023-03-27 2022-11-14
acceptedDate 2025-11-12 16:17:11 2025-08-07 16:30:40 2024-11-08 16:05:54 2024-08-08 16:10:40 2024-05-09 16:15:33 2024-04-01 17:01:09 2023-11-08 16:16:06 2023-08-09 13:27:44 2023-05-12 16:23:43 2023-03-27 16:38:59 2022-11-14 16:54:55
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 10000 -640 000 1M 2M 572 000 813 000 -528 000 175 000 351 000 -2M -14M
depreciationAndAmortization 111 000 199 000 189 000 188 000 160 000 45 000 240 000 358 000 356 000 354 000 635 000
deferredIncomeTax 0 0 0 0 0 -111 000 -314 999 0 0 -93 000 0
stockBasedCompensation 7000 9000 86 000 53 000 79 000 129 000 152 000 157 000 192 000 125 000 520 000
changeInWorkingCapital 0 959 000 153 000 -853 000 -808 000 -831 000 1M -499 000 218 000 -550 000 -3M
accountsReceivables 0 2M 0 -1M -49 000 -153 000 699 000 -814 000 317 000 -240 000 395 000
inventory 0 0 0 0 0 1 -1 0 0 0 0
accountsPayables 0 -470 000 0 163 000 -176 000 261 000 -382 000 78 000 532 000 -288 000 -1M
otherWorkingCapital 0 -108 000 153 000 184 000 -583 000 -939 000 712 000 237 000 -849 000 -22 000 -2M
otherNonCashItems -128 000 -7000 408 000 1M 563 000 1M 527 000 220 000 16 000 1M 13M
netCashProvidedByOperatingActivities 0 520 000 2M 1M -58 000 1M 1M 411 000 1M -276 000 -3M
investmentsInPropertyPlantAndEquipment 0 -201 000 0 -197 000 -28 000 -142 000 -152 000 -111 000 -65 000 -196 000 -40 000
acquisitionsNet 0 0 0 0 0 -117 000 500 000 -117 000 0 -903 000 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -522 000 -225 000 0 117 000 500 000 0 0 0 7M
netCashUsedForInvestingActivites 0 -201 000 -522 000 -197 000 -28 000 -142 000 348 000 -228 000 -65 000 -1M 7M
debtRepayment 0 -1 000 000 -2M -2M -600 000 -3M -2M -700 000 0 0 0
commonStockIssued 0 0 0 0 0 0 0 0 0 2000 47 000
commonStockRepurchased 0 0 0 0 0 -32 000 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 -13 000 0 0 -600 000 -3M -2M 0 -300 000 -108 000 0
netCashUsedProvidedByFinancingActivities 0 -1M -2M -2M -600 000 -3M -2M -700 000 -300 000 -106 000 47 000
effectOfForexChangesOnCash 0 0 0 0 0 -1M 0 1M 0 0 0
netChangeInCash 0 -694 000 94 000 -793 000 -686 000 -2M -547 000 -517 000 768 000 -1M 4M
cashAtEndOfPeriod 0 502 000 2M 2M 3M 3M 5M 5M 6M 5M 6M
cashAtBeginningOfPeriod 0 1M 2M 3M 3M 5M 6M 6M 5M 6M 2M
operatingCashFlow 0 520 000 2M 1M -58 000 1M 1M 411 000 1M -276 000 -3M
capitalExpenditure 0 -201 000 -522 000 -197 000 -28 000 -142 000 -152 000 -111 000 -65 000 -196 000 -40 000
freeCashFlow 0 319 000 2M 1M -86 000 998 000 953 000 300 000 1M -472 000 -3M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-12-03 16:05 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-12-03 16:05 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-11-12 16:45 ET
Interpace Biosciences published news for 2025 q3
SEC form 8
2025-11-12 16:45 ET
Interpace Biosciences reported for 2025 q3
SEC form 10
2025-11-12 16:17 ET
Interpace Biosciences reported for 2025 q3
SEC form 8
2025-08-08 16:28 ET
Interpace Biosciences published news for 2025 q2
SEC form 8
2025-08-08 16:28 ET
Interpace Biosciences reported for 2025 q2
SEC form 10
2025-08-07 20:30 ET
Interpace Biosciences reported for 2025 q2
SEC form 10
2025-05-08 20:28 ET
Interpace Biosciences reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Interpace Biosciences reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Interpace Biosciences published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Interpace Biosciences reported for 2025 q1
SEC form 8
2025-04-30 23:31 ET
Interpace Biosciences published news for 2025 q1
SEC form 8
2025-04-30 23:31 ET
Interpace Biosciences published news for 2025 q1
SEC form 10
2025-03-31 16:01 ET
Interpace Biosciences published news for 2024 q4
SEC form 10
2025-03-31 00:00 ET
Interpace Biosciences published news for 2024 q4
SEC form 8
2025-01-27 21:15 ET
Interpace Biosciences published news for 2024 q4
SEC form 8
2025-01-27 21:15 ET
Interpace Biosciences published news for 2024 q4
SEC form 10
2024-11-08 16:05 ET
Interpace Biosciences reported for 2024 q3
SEC form 8
2024-11-06 16:46 ET
Interpace Biosciences published news for 2024 q3
SEC form 8
2024-11-06 16:46 ET
Interpace Biosciences published news for 2024 q3
SEC form 10
2024-08-08 00:00 ET
Interpace Biosciences published news for 2024 q2
SEC form 8
2024-08-02 16:30 ET
Interpace Biosciences published news for 2024 q2
SEC form 8
2024-08-02 16:30 ET
Interpace Biosciences reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Interpace Biosciences reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Interpace Biosciences published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Interpace Biosciences published news for 2024 q1
SEC form 10
2024-04-01 17:01 ET
Interpace Biosciences published news for 2023 q4
SEC form 10
2024-04-01 00:00 ET
Interpace Biosciences published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
Interpace Biosciences published news for 2023 q4
SEC form 8
2024-03-13 00:00 ET
Interpace Biosciences reported for 2023 q4
SEC form 8
2023-11-08 17:14 ET
Interpace Biosciences published news for 2023 q3
SEC form 10
2023-11-08 16:16 ET
Interpace Biosciences reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Interpace Biosciences published news for 2023 q3
SEC form 6
2023-08-09 15:47 ET
Interpace Biosciences published news for 2023 q2
SEC form 10
2023-08-09 13:27 ET
Interpace Biosciences reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Interpace Biosciences published news for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Interpace Biosciences published news for 2023 q2
SEC form 6
2023-08-01 20:59 ET
Interpace Biosciences published news for 2023 q2
SEC form 6
2023-05-12 16:34 ET
Interpace Biosciences published news for 2023 q1
SEC form 10
2023-05-12 16:23 ET
Interpace Biosciences published news for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Interpace Biosciences published news for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-04-28 16:15 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-04-24 20:56 ET
Interpace Biosciences published news for 2023 q1
SEC form 6
2023-03-27 16:42 ET
Interpace Biosciences published news for 2022 q4
SEC form 10
2023-03-27 16:38 ET
Interpace Biosciences reported for 2022 q4
SEC form 10
2023-03-27 00:00 ET
Interpace Biosciences reported for 2022 q4
SEC form 8
2023-03-27 00:00 ET
Interpace Biosciences reported for 2022 q4
SEC form 6
2022-11-15 16:09 ET
Interpace Biosciences published news for 2022 q3
SEC form 10
2022-11-14 16:54 ET
Interpace Biosciences reported for 2022 q3
SEC form 6
2022-11-14 16:52 ET
Interpace Biosciences published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Interpace Biosciences reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Interpace Biosciences reported for 2022 q3
SEC form 6
2022-11-04 16:33 ET
Interpace Biosciences published news for 2022 q3
SEC form 6
2022-10-04 16:18 ET
Interpace Biosciences published news for 2022 q3
SEC form 6
2022-09-20 16:36 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-09-09 16:28 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-09-07 16:46 ET
Interpace Biosciences published news for 2022 q2
SEC form 6
2022-08-15 17:42 ET
Interpace Biosciences published news for 2022 q2
SEC form 10
2022-08-15 16:47 ET
Interpace Biosciences reported for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Interpace Biosciences reported for 2022 q2
SEC form 8
2022-08-15 00:00 ET
Interpace Biosciences reported for 2022 q2
SEC form 10
2022-05-16 16:31 ET
Interpace Biosciences reported for 2022 q1
SEC form 6
2022-05-16 16:28 ET
Interpace Biosciences published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Interpace Biosciences reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Interpace Biosciences reported for 2022 q1
SEC form 6
2022-05-10 16:30 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-04-29 18:24 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-04-14 16:05 ET
Interpace Biosciences published news for 2022 q1
SEC form 6
2022-03-31 16:37 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2022-03-31 16:35 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Interpace Biosciences published news for 2021 q4
SEC form 8
2022-03-31 00:00 ET
Interpace Biosciences published news for 2021 q4
SEC form 6
2022-01-28 19:38 ET
Interpace Biosciences published news for 2021 q4
SEC form 6
2022-01-27 16:15 ET
Interpace Biosciences published news for 2021 q4
SEC form 10
2021-11-10 16:31 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-10 16:16 ET
Interpace Biosciences published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Interpace Biosciences published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-09 21:58 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-11-02 21:55 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-10-18 21:48 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-10-01 17:21 ET
Interpace Biosciences published news for 2021 q3
SEC form 6
2021-09-27 16:29 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-31 16:48 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-20 17:29 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-20 17:27 ET
Interpace Biosciences published news for 2021 q2
SEC form 10
2021-08-11 00:00 ET
Interpace Biosciences published news for 2021 q2
SEC form 10
2021-08-10 21:48 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-10 16:52 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-08-06 16:27 ET
Interpace Biosciences published news for 2021 q2
SEC form 6
2021-06-29 17:17 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-05-11 17:06 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-05-11 17:03 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-05-11 00:00 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-04-29 16:05 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-04-05 06:30 ET
Interpace Biosciences published news for 2021 q1
SEC form 10
2021-04-01 06:14 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-04-01 06:02 ET
Interpace Biosciences published news for 2021 q1
SEC form 6
2021-02-24 20:04 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-02-17 17:00 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-02-04 16:49 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-20 08:55 ET
Interpace Biosciences published news for 2020 q4
SEC form 10
2021-01-19 21:43 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2021-01-19 17:03 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-19 16:59 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-19 16:54 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2021-01-11 16:50 ET
Interpace Biosciences published news for 2020 q4
SEC form 6
2020-12-07 21:49 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-25 08:25 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-19 16:20 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-11-17 16:19 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-10-23 16:01 ET
Interpace Biosciences published news for 2020 q3
SEC form 6
2020-10-20 08:35 ET
Interpace Biosciences published news for 2020 q3
SEC form 10
2020-10-19 17:13 ET
Interpace Biosciences published news for 2020 q2
SEC form 6
2020-10-14 09:14 ET
Interpace Biosciences published news for 2020 q3